Can I get a prescription for BPC-157?

No, in the United States. BPC-157 has no legal prescription pathway as of late 2023. The FDA's Pharmacy Compounding Advisory Committee voted in November 2023 against adding BPC-157 to the 503A bulks list, which closed off the compounding-pharmacy route — the main avenue through which BPC-157 was being legitimately prescribed previously. BPC-157 is not FDA-approved and not on a controlled-substance schedule; it is currently only available as a research chemical from research-chem vendors. By contrast, Tesamorelin (Egrifta, FDA-approved for HIV-LD) and Sermorelin (compounding-pharmacy in some jurisdictions) do have legitimate prescription pathways.

Why BPC-157 can't be prescribed in the US

A US prescription requires either an FDA-approved drug product or a compounded preparation under the 503A or 503B framework. BPC-157 fits neither:

• Not FDA-approved — BPC-157 has never been approved as a new drug for any human indication
• Excluded from 503A compounding — the November 2023 FDA committee vote concluded it shouldn't be on the bulks list, citing insufficient safety data
• Excluded from 503B compounding — outsourcing facilities follow a separate but similarly restrictive list
• Not a controlled substance — possession isn't a federal drug-possession offense, but that doesn't create a prescription pathway

A US physician writing a "BPC-157 prescription" today is writing a prescription that no legitimate pharmacy can legally fill from a compounding pathway. Some operators continue to write and dispense BPC-157 prescriptions despite the ruling; this is regulatorily exposed for the prescriber and pharmacy, not a normalized practice.

See the FDA BPC-157 503A status for the full timeline.

What changed in November 2023

The specifics of the regulatory event:

• The FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed BPC-157 for inclusion on the 503A bulks list
• The committee voted against inclusion
• Cited reasons: insufficient safety data, unclear pharmacology, manufacturing standards questions
• The vote effectively closed the 503A compounding route for BPC-157
• The vote did not make BPC-157 illegal to possess, did not schedule it, and did not change its research-chem status

Before November 2023, some compounding pharmacies were producing BPC-157 for prescriptions in a regulatory gray area. The vote ended the gray area. Pharmacies operating in good faith largely ceased BPC-157 compounding after the ruling.

The peptides that CAN be prescribed

For comparison, here are strength-adjacent peptides with legitimate prescription pathways:

Tesamorelin is the only fully FDA-approved member of the strength-peptide adjacency. Sermorelin's 503A status varies by jurisdiction, but compounding-pharmacy access exists in many states. Most other strength peptides are research-chem only with no prescription pathway.

What about telemedicine clinics offering BPC-157?

A handful of telemedicine providers have continued to offer BPC-157 alongside legitimately prescribable peptides. The regulatory situation for these operators changed materially after November 2023:

• Compounding pharmacies legally cannot produce BPC-157 from the 503A bulks pathway
• Some operators source BPC-157 from research-chem suppliers and dispense it under prescription branding — this is regulatorily exposed
• Some operators have stopped offering BPC-157 entirely after the ruling
• Some have relabeled or repositioned their offerings

A telemedicine "prescription" for BPC-157 is not the same regulatory product as a legitimate compounded prescription. Buyers should understand which category they're actually purchasing from.

What about Sermorelin or Tesamorelin instead?

If the underlying goal is access to a peptide via a legitimate prescription pathway, the prescribable options are Tesamorelin and Sermorelin. They aren't substitutes for BPC-157's tissue-repair effects — they're growth-hormone secretagogues with different mechanisms — but they exist within the regulatory system in a way BPC-157 doesn't.

Different peptides for different goals. Substituting Tesamorelin for BPC-157 is substituting "raise GH" for "heal a tendon" — these aren't the same.

What about international prescriptions?

A few countries permit BPC-157 compounding more permissively than the US. This isn't a recommendation to import compounded preparations across borders — see customs and importation. The regulatory landscape for compounded peptides varies widely between countries; what's compoundable in one jurisdiction isn't necessarily in another.

For jurisdiction-specific guidance, talk to a lawyer.

Bottom line

In the US, there is no legal prescription pathway for BPC-157 as of late 2023. The available access route is research-chem vendors, with the regulatory and quality considerations that come with that channel. Tesamorelin and Sermorelin are the strength-adjacent peptides with real prescription pathways. If the goal specifically requires a prescription, those are the peptides — not BPC-157. For jurisdiction-specific or case-specific advice, talk to a lawyer.

Related questions

• Are peptides legal in the US?
• Do I need a doctor for peptides?
• How long does BPC-157 take to work?
• FDA BPC-157 503A compounding status